

Price Waterhouse Chartered Accountants LLP

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of Amanta Healthcare Limited

Report on the Audit of Financial Results

Opinion

1. We have audited the accompanying annual financial results of Amanta Healthcare Limited (the "Company") for the year ended March 31, 2026 and the Statement of Assets and Liabilities as on that date and the Statement of Cash Flows for the year ended on that date, attached herewith, which are included in the accompanying 'Statement of Financial Results for the Quarter and Year ended March 31, 2026' (together referred to as the "financial results") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations") which has been initialed by us only for identification purposes.
2. In our opinion and to the best of our information and according to the explanations given to us, the financial results:
 - (i) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
 - (ii) give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 (the "Act") and other accounting principles generally accepted in India, of net profit and other comprehensive income and other financial information of the Company for the year ended March 31, 2026 and the Statement of Assets and Liabilities and the Statement of Cash Flows as at and for the year ended on that date.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Act and other applicable authoritative pronouncements issued by the Institute of Chartered Accountants of India. Our responsibilities under those Standards are further described in the 'Auditor's Responsibilities for the Audit of the Financial Results' section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.



Price Waterhouse Chartered Accountants LLP, 17th Floor, Shapath V, Opp. Karnavati Club, S G Highway
Ahmedabad - 380 051, Gujarat, India
T: +91 (79) 69247156

Registered office and Head office: 11-A, Vishnu Digamber Marg, Sucheta Bhawan, New Delhi - 110002

Price Waterhouse (a Partnership Firm) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post its conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/N500016 (ICAI registration number before conversion was 012754N)

Price Waterhouse Chartered Accountants LLP

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of Amanta Healthcare Limited

Report on the Financial Results

Page 2 of 3

Board of Directors' Responsibilities for the Financial Results

4. These financial results have been prepared on the basis of the annual financial statements. The Company's Board of Directors are responsible for the preparation and presentation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Company and the statement of assets and liabilities and the statement of cash flows in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Board of Directors of the Company are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the financial results by the Directors of the Company, as aforesaid.
5. In preparing the financial results, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
6. The Board of Directors of the Company are responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Financial Results

7. Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.
8. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
 - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.



Price Waterhouse Chartered Accountants LLP

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of Amanta Healthcare Limited

Report on the Financial Results

Page 3 of 3

- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
 - Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.
9. We communicate with those charged with governance of the Company regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
10. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

11. The financial results include the results for the quarter ended March 31, 2026 being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year, which were subject to limited review by us.
12. The financial results for the quarter ended March 31, 2025, included in the Statement of Financial Results were neither audited nor subject to limited review by the statutory auditors of the company as the company has got listed for the first time during the quarter ended June 30, 2025.

For Price Waterhouse Chartered Accountants LLP

Firm Registration Number: 012754N/N500016



Devang Mehta

Partner

Membership Number: 118785

UDIN: 26118785 AUF CVW 7057

Place: Ahmedabad

Date: May 19, 2026

AMANTA HEALTHCARE LIMITED						
Registered Office: 8Th Floor, Shaligram Corporates C.J. Marg, Ambli, Ahmedabad - 380058, Gujarat, India, CIN: L24139GJ1994PLC023944. Phone: +91 79 6777 7600, E-mail: info@amanta.co.in, Website: www.amanta.co.in						
STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026						
Sr.no.	Particulars	For the quarter ended			(Rs. in lakhs)	
					For the year ended	
		31.03.2026 Un-audited (Refer note 7)	31.12.2025 Un-audited	31.03.2025 Un-audited (Refer note 2 and 7)	31.03.2026 Audited	31.03.2025 Audited
I	Income					
	Revenue from operations	7,699.49	7,448.74	7,206.28	28,767.67	27,470.82
	Other income	166.21	67.70	16.20	337.07	138.52
	Total income	7,865.70	7,516.44	7,222.48	29,104.74	27,609.34
II	Expenses					
	Cost of material consumed	2,513.04	2,423.50	2,573.80	9,692.95	10,126.14
	Purchase of stock-in-trade	354.58	242.15	448.44	1,060.90	1,232.04
	Changes in inventories of finished goods, work-in-process and stock-in-trade	19.08	(36.84)	(575.02)	(1,089.29)	(1,952.65)
	Employee benefits expense	1,108.84	1,097.76	930.89	4,296.11	3,633.97
	Finance costs (Refer note 6)	424.64	506.08	628.11	2,074.57	2,794.79
	Depreciation and amortisation expense	475.18	467.43	469.41	1,873.00	1,839.89
	Other expenses	2,208.67	2,186.00	1,931.82	8,821.15	8,464.47
	Total expenses	7,104.03	6,886.08	6,407.45	26,729.39	26,138.65
III	Profit before exceptional item and tax for the period / year (I-II)	761.67	630.36	815.03	2,375.35	1,470.69
IV	Exceptional item (Refer note 5)	-	-	-	262.88	-
V	Profit before tax (III - IV)	761.67	630.36	815.03	2,112.47	1,470.69
VI	Tax expense					
	- Current Tax	292.98	207.24	184.74	855.53	362.49
	- Deferred Tax	(84.47)	(36.60)	37.63	(234.01)	61.40
	- Tax adjustment in respect of earlier year	-	(3.17)	(3.27)	3.43	(3.27)
	Total tax expenses	208.51	167.47	219.10	624.95	420.62
VII	Profit for the period/year (V - VI)	553.16	462.89	595.93	1,487.52	1,050.07
VIII	Other comprehensive income					
	Items that will not be reclassified to profit and loss					
	Remeasurement (loss) on the defined benefit plans	(56.33)	(13.41)	(20.66)	(96.55)	(53.62)
	Tax relating to remeasurement (loss) of the defined benefit plans	14.18	3.37	5.20	24.30	13.50
	Other comprehensive income (net of tax)	(42.15)	(10.04)	(15.46)	(72.25)	(40.12)
IX	Total comprehensive income (VII+VIII)	511.01	452.85	580.47	1,415.27	1,009.95
	Paid up equity share capital (Face value of Rs. 10/- each)	343.36	343.36	282.70	343.36	282.70
	Reserves excluding revaluation reserves as per balance sheet of previous accounting year				18,138.16	6,755.89
	Earnings per share (of Rs. 10/- each) Basic and Diluted (Rs.)	1.61 *	1.35 *	2.11 *	4.33	3.71
	*(not annualised)					



Amanta Healthcare Limited

Registered Office: 8Th Floor, Shaligram Corporates C.J. Marg, Ambli, Ahmedabad - 380058, Gujarat, India, CIN: L24139GJ1994PLC023944.
Phone: +91 79 6777 7600, E-mail: info@amanta.co.in, Website: www.amanta.co.in

Statement of Assets And Liabilities as at March 31, 2026

(Rs. in lakhs)		
Particulars	As at March 31, 2026	As at March 31, 2025
	Audited	Audited
Assets		
Non-Current Assets		
(a) Property, plant and equipment	19,725.11	20,767.53
(b) Right-of-use assets	924.23	854.58
(c) Capital work-in-progress	8,151.77	654.80
(d) Intangible assets	68.72	91.63
(e) Financial Assets		
(i) Loans	33.44	20.70
(ii) Investments	704.67	772.29
(iii) Other Financial Assets	853.80	91.57
(f) Non current tax assets (net)	-	0.11
(g) Other non-current assets	1,483.59	1,130.72
	31,945.33	24,383.93
Current Assets		
(a) Inventories	8,270.94	7,297.69
(b) Financial Assets		
(i) Trade receivables	4,302.35	5,008.47
(ii) Cash and cash equivalents	8,101.03	22.06
(iii) Bank balances other than cash and cash equivalents	1,162.65	325.67
(iv) Loans	50.71	45.22
(v) Other financial Assets	30.70	1.75
(c) Other current assets	1,934.36	1,091.06
	23,852.74	13,791.92
Total Assets	55,798.07	38,175.85
Equity And Liabilities		
Equity		
(a) Equity Share capital	3,882.94	2,882.94
(b) Other Equity	18,138.16	6,755.89
	22,021.10	9,638.83
Liabilities		
Non-Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	16,197.06	13,235.75
(ii) Lease Liabilities	799.62	773.93
(b) Deferred tax liabilities (net)	2,674.61	3,019.08
	19,671.29	17,028.76
Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	7,244.75	6,263.86
(ii) Lease Liabilities	202.90	120.11
(iii) Trade payables		
(A) Total outstanding dues of micro enterprises and small enterprises;	343.19	221.77
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises		
(iv) Other Financial Liabilities	3,246.20	2,828.17
(b) Contract liabilities	706.39	349.99
(c) Other current liabilities	887.52	620.87
(d) Provisions	111.55	190.88
(e) Current Tax Liabilities (net)	1,057.20	800.96
	305.98	111.65
	14,105.68	11,508.26
Total Equity and Liabilities	55,798.07	38,175.85



Amanta Healthcare Limited

Registered Office: 8Th Floor, Shaligram Corporates C.J. Marg, Ambli, Ahmedabad - 380058, Gujarat, India, CIN: L24139GJ1994PLC023944.

Statement of Cash Flows for the year ended March 31, 2026

Particulars	(Rs. in lakhs)	
	Year ended March 31, 2026 (Audited)	Year ended March 31, 2025 (Audited)
Cash Flow From Operating Activities		
Profit before tax	2,112.47	1,470.69
Adjustments for :		
Depreciation and amortization expense	1,873.00	1,839.89
Loss on disposal of property, plant and equipment (net)	5.01	9.95
Net unrealised loss / (gain) on foreign currency transactions	(60.92)	4.28
Exceptional Item	262.88	-
Loss allowance on trade receivable	104.83	131.69
Finance costs	2,074.57	2,794.79
Interest Income	(126.17)	(30.92)
Liabilities written back to the extent no longer required	(7.04)	(18.53)
Unwinding of discount on security deposits	(3.18)	(4.75)
Changes in fair value of financial assets measured at fair value through profit and loss	(44.83)	(50.11)
Profit before change in operating assets and liabilities	6,190.62	6,146.98
Adjustment for changes in operating assets and liabilities:		
Adjustments for decrease / (increase) in operating assets:		
Inventories	(973.25)	(1,352.93)
Trade receivables	671.09	(130.81)
Loans	(18.23)	(35.44)
Other financial asset	(36.91)	9.57
Other assets	(1,206.08)	(117.51)
Adjustments for increase / (decrease) in operating liabilities:		
Trade payables	523.53	551.21
Other current financial liabilities	68.37	55.62
Contract liabilities	266.65	(221.45)
Other current liabilities	(191.67)	(17.55)
Short term provision	256.24	154.31
Cash generated from operations	5,550.36	5,042.00
Taxes paid (net of tax refund)	(705.72)	(380.00)
Net cash flow from operating activities	4,844.64	4,662.00
Cash flow from investing activities		
Payments for property, plant and equipment, intangible assets and capital work in progress and capital advances	(8,018.64)	(2,077.40)
Investments in bank deposits (having maturity more than three months but less than twelve months) (net)	(1,544.23)	(69.33)
Investment in Mutual Fund	(420.00)	(350.00)
Proceed from sales of Mutual Fund	532.43	-
Interest received on deposits	74.22	30.92
Proceeds from disposal of property, plant and equipment	15.33	18.56
Net cash used in investing activities	(9,360.89)	(2,447.25)



Statement of Cash Flows for the year ended March 31, 2026

Particulars	(Rs. in lakhs)	
	Year ended	Year ended
	March 31, 2026	March 31, 2025
	(Audited)	(Audited)
Cash flow from financing activities		
Repayment of non convertible debenture	-	(12,179.96)
Proceed from issue of equity shares (including securities premium)	12,600.00	2,000.00
Share issue expenses	(1,665.16)	-
Proceeds from term loans -Secured	2,620.78	44.54
Repayment of term loans -Secured	(226.89)	(448.58)
Repayment of term loan -Unsecured	(103.26)	(89.12)
Proceeds from deposits from members	137.76	178.00
Repayment of deposits from members	(952.65)	(254.28)
Proceeds/payment from cash credit (net)	108.81	(216.44)
Proceeds from term loan from financial institutions	5,103.32	12,575.00
Repayment of term loans from financial institutions	(1,655.94)	(800.00)
Repayment of Non-Convertible Redeemable Preference Share	(1,133.74)	-
Interest paid on non convertible debenture	-	(65.04)
Dividend paid on Non-Convertible Redeemable Preference Share	(40.46)	(100.00)
Transaction cost related to proposed Initial Public Offering	-	(316.88)
Processing Fees on term loan from financial institutions	(31.50)	(381.00)
Interest paid on term loan	(214.94)	(256.32)
Interest paid for term loan from financial institutions	(1,385.09)	(1,328.86)
Interest paid on cash credit	(238.76)	(302.87)
Interest paid on deposits from members	(37.54)	(83.15)
Payment of other borrowings cost	(72.32)	(98.22)
Payment of principal of lease liabilities	(217.20)	(223.45)
Net cash from/(used) in financing activities	12,595.22	(2,346.63)
Net increase/(decrease) in cash and cash equivalents	8,078.97	(131.88)
Cash and cash equivalents as at beginning of the year	22.06	153.94
Cash and cash equivalents as at end of the year	8,101.03	22.06
Footnotes:		
Cash and cash equivalents as at end of the year:		
Balances with banks		
Balances in current accounts	6,599.60	4.92
Cash on hand	13.26	17.14
Fixed Deposit having original maturity of less than 3 months	1,488.17	-
Cash and cash equivalents as per Balance Sheet	8,101.03	22.06



Notes:

- 1 The above audited financial results are prepared in compliance with Indian Accounting Standard ("Ind AS") as notified under section 133 of the Companies Act, 2013 ("the Act") [Companies (Indian Accounting Standards) Rules, 2015], as amended. The above audited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 19, 2026.
- 2 The figures for the corresponding quarter ended March 31, 2025 as reported in these audited financial results have been approved by the Company's Board of Directors but have not been subjected to review since the requirement of submission of quarterly financial results is applicable on listing of equity shares of the Company, which was from the quarter ended June 30, 2025. These figures are furnished by the management of the Company and were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on May 19, 2026.
- 3 The Company operates only in one business segment i.e. Manufacturing and sale of pharmaceutical products including contract manufacturing services provided to customer which constitutes single reportable segment in accordance with the requirements of Ind AS 108 "Operating Segments".
- 4 During the quarter ended September 30, 2025, the Company has completed its Initial Public Offer (IPO) where 10,000,000 equity shares of face value of Rs. 10 each have been issued at a price of Rs. 126 per share. The issue comprised of 100% fresh issue aggregating to Rs. 12,600 lakhs. Pursuant to IPO, the equity shares of the Company were listed on BSE Limited and National Stock Exchange of India Limited on September 09, 2025. The utilization of the IPO proceeds from fresh issue of Rs. 12,600 lakhs is summarized below: -

Particulars	Amount to be utilized as per prospectus (Rs. In lakhs)	Revised Cost of objects (Rs in lakhs)	Amount utilized upto March 31, 2026 (Rs. In lakhs)	Amount unutilized as at March 31, 2026 (Rs. In lakhs) (Refer Note a below)	Delay in utilisation
Funding capital expenditure requirements for civil construction work and towards purchase of equipment, plant and machinery for setting up new manufacturing line of SteriPort at Hariyala, Kheda, Gujarat	7,000.00	7,000.00	4,766.36	2,233.64	Rs. 2,233.64 lakhs Refer note b below
Funding capital expenditure requirements towards civil construction work, purchase of equipment, plant and machinery for setting up new manufacturing line for SVP at Hariyala, Kheda, Gujarat	3,013.11	3,013.11	-	3,013.11	Rs. 1,000.00 lakhs Refer note b below
General corporate purposes*	660.46	302.08	302.08	-	-
Issue Expenses*	1,926.43	2,284.81	2,284.81	-	-
Total	12,600.00	12,600.00	7,353.25	5,246.75	-


* The issue expenses are modified to the extent of GST payment made over the cost as per the Offer Document filed for the IPO as certified by Independent Chartered Accountant and affirmed by the monitoring agency. Consequent to this, general corporate purpose expenses are also modified and reduced to that extent.

Note a: IPO proceeds which were unutilised as at March 31, 2026 are temporarily invested in fixed deposits and kept in monitoring account. Interest earned on fixed deposits and utilised for the objects is Rs. 34.67 lakhs and interest accrued on the fixed deposits as at March 31, 2026 is Rs. 42.26 lakhs.

Note b: The Company had estimated to utilize Rs 8,000.00 lakhs for the above mentioned objects by FY 2026. The delay is primarily attributable to (a) deferment of payments to suppliers on account of pending completion of work/supply of goods against agreed milestones; and (b) delay in placement of machinery orders owing to pending finalization of commercial terms with the respective suppliers.

- 5 The Company has incurred certain IPO related expenses which have been allocated on a rational basis. The cost of Rs. 1,719.16 lakhs (net of GST) allocated for issue of new shares has been adjusted against securities premium as permissible under Section 52 of the Companies Act, 2013 upon successful completion of Initial Public Offer (IPO). The cost of Rs. 262.88 lakhs (net of GST) allocated for listing of existing shares has been recognised in the Statement of Profit and Loss and disclosed as an exceptional item.
- 6 The finance costs for the year ended March 31, 2025 includes Rs. 309.73 lakhs, being cost of derecognition of financial liability consequent to the early redemption of non-convertible debentures.
- 7 Figures of the quarters ended March 31, 2026 are the balancing figures between the audited figures for the year ended on that date and the unaudited published year to date figures up to the nine months period ended.
- 8 On November 21, 2025, the Government of India notified the four consolidated Labour Codes, replacing several existing labour laws. Based on the draft rules and the guidance currently available, the Company has evaluated the impact of the revised definition of wages on its employee benefit obligations in accordance with Ind AS 19. Following this assessment the incremental impact arising from the implementation of the Labour Codes is not material to its financial performance. The Company will continue to monitor the finalisation of the relevant Central and State Rules and will recognise additional impact, if any, in the period in which such Rules or related clarifications are notified.

For and on behalf of Board of Directors



Bhavesh Patel
Chairman and Managing Director
DIN: 00085505

Place: Ahmedabad
Date: May 19, 2026



Registered & Corporate Office:
Amanta Healthcare Ltd.
8th Floor, Shaligram Corporates, C. J. Marg,
Ambli, Ahmedabad 380058, Gujarat, INDIA.
Tel.: +91 79 67777600
Email : info@amanta.co.in Website : www.amanta.co.in
CIN : L24139GJ1994PLC023944

CERTIFICATE
Pursuant to Regulation 33 of
SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

We the undersigned, Bhavesh Patel, Chairman & Managing Director and Paras Mehta, Chief Financial Officer of M/s. Amanta Healthcare Limited, hereby jointly certify that the enclosed Financial Results for the Quarter and Year ended on March 31, 2026 do not contain any false or misleading statement or figures and do not omit any material fact which may make the statements or figures contained therein misleading.

For Amanta Healthcare Limited,



Bhavesh G. Patel
Chairman & Managing Director,



Paras Mehta
Chief Financial Officer

Date: May 19, 2026
Place: Ahmedabad

